Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease

PURPOSE: In a 10-week proof-of-concept study (LINC 1), the potent oral 11β-hydroxylase inhibitor osilodrostat (LCI699) normalized urinary free cortisol (UFC) in 11/12 patients with Cushing’s disease. The current 22-week study (LINC 2; NCT01331239) further evaluated osilodrostat in patients with Cush...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleseriu, Maria, Pivonello, Rosario, Young, Jacques, Hamrahian, Amir H., Molitch, Mark E., Shimizu, Chikara, Tanaka, Tomoaki, Shimatsu, Akira, White, Tracy, Hilliard, Annie, Tian, Chuan, Sauter, Nicholas, Biller, Beverly MK, Bertagna, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799251/
https://www.ncbi.nlm.nih.gov/pubmed/26542280
http://dx.doi.org/10.1007/s11102-015-0692-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4799251/
https://www.ncbi.nlm.nih.gov/pubmed/26542280
http://dx.doi.org/10.1007/s11102-015-0692-z

Ejemplares similares